Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects.
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism*; D002746:Chlorpromazine / Q000378:metabolism; D003024:Clozapine / Q000378:metabolism; D005476:Fluphenazine / Q000378:metabolism; D006168:Guinea Pigs; D006220:Haloperidol / Q000378:metabolism; D000882:Haplorhini; D006801:Humans; D066298:In Vitro Techniques; D010546:Perphenazine / Q000378:metabolism; D010640:Phenothiazines / Q000378:metabolism; D011395:Promazine / Q000378:metabolism; D051381:Rats; D011950:Receptors, Cholinergic; D012559:Schizophrenia / Q000188:drug therapy*; D013881:Thioridazine / Q000378:metabolism; D014268:Trifluoperazine / Q000378:metabolism; D014273:Triflupromazine / Q000378:metabolism
D014150:Antipsychotic Agents; D010640:Phenothiazines; D011950:Receptors, Cholinergic; D014268:Trifluoperazine; D010546:Perphenazine; D003024:Clozapine; D006220:Haloperidol; D013881:Thioridazine; D011395:Promazine; D014273:Triflupromazine; D005476:Fluphenazine; D002746:Chlorpromazine